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Background & Aims: Little is known about risk of upper gastrointestinal bleeding 
(UGIB) in patients failed by Helicobacter pylori eradication therapy. We investigated 
the effects of different time until retreatment, after failure of initial H pylori eradication 
therapy, on subsequent risk of UGIB. 
 
Methods: We performed a territory-wide retrospective cohort study of 70,518 patients 
with H pylori infection who had received their first course of clarithromycin-based 
triple therapy from January 2003 through December 2012 in Hong Kong. Patients who 
required retreatment after failed initial therapy (n= 8330, 11.8%) were categorized 
based on time between initial and final H pylori eradication (3 months or less, 3–12 
months, and more than 12 months). We collected clinical data from 30 days after 
prescription of the last course of H pylori therapy until hospitalization for non-variceal 
UGIB, death, or the end of the study (30 Jun 2016; median follow-up time, 7.65 years). 
The primary outcome was difference in development UGIB (determined from ICD-9 
codes) between patients who required retreatment and those who did not (reference 
group). 
 
Results: Compared with the reference group, patients who required retreatment had an 
overall higher risk of UGIB, even after last eradication therapy (adjusted hazard ratio 
(HR), 1.50, 95% CI, 1.34–1.69). There was a progressive increase in risk of UGIB with 
longer time from initial until final eradication therapy: hazard ratio for time less than 3 
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months, 1.16; 95% CI, 0.88–1.54, hazard ratio for time 3–12 months, 1.35; 95% CI, 
1.07–1.69, and hazard ratio for time more than 12 months, 1.68; 95% CI, 1.46–1.94 (P 
for trend = .038). 
 
Conclusion: In a retrospective study of patients in Hong Kong, we found that those 
failed by initial H pylori eradication have an increased risk of UGIB, compared to 
patients who responded to the initial therapy. Risk increased progressively with longer 
time until retreatment. Early retreatment within 3 months should be considered to 
minimize subsequent UGIB risk. 
 




Helicobacter pylori (H pylori) infection is an independent risk factor for peptic ulcer 
disease and previous studies showed that 43-56% of patients with peptic ulcer bleeding 
(PUB) were infected with H pylori.1 Since H pylori eradication could significantly 
decrease the risk of peptic ulcer and recurrent ulcer bleeding,2, 3 treatment for H pylori 
is recommended in all infected patients with peptic ulcer. Moreover, test and treat 
strategy for H pylori should also be considered in high-risk patients with prior history 
of upper gastrointestinal bleeding (UGIB) or ulcer, concomitant use of aspirin or 
nonsteroidal anti-inflammatory drugs (NSAIDs).4 
 
A recent study from Sweden showed that even a slight delay in primary H pylori 
eradication therapy after diagnosis of peptic ulcer would increase the risk of ulcer 
complications in a time-dependent manner.5 With the increasing prevalence of 
antimicrobial resistance worldwide, the eradication rate of the conventional 
clarithromycin-based triple therapy continues to decline.6, 7 However, the risks of 
subsequent UGIB in patients who failed initial H pylori eradication therapy remain 
poorly defined. Kalkan et al.8 reported that the prevalence of severe gastritis was higher 
in patients who failed H pylori eradication. Therefore, the risks of subsequent UGIB 
could be different in patients who failed initial eradication and required retreatment 
when compared to those with successful H pylori eradication. Moreover, it is unclear 
about the best latency interval in retreatment to avoid complications like PUB. 
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In this territory-wide study involving a large cohort of H. pylori-infected patients who 
had received their first course of clarithromycin based triple therapy in Hong Kong, we 
compared the risk of hospitalization for UGIB in patients who needed retreatment for 
H pylori to those who received a single course of eradication therapy. We also 
determined the effect of different time intervals between the first and last H pylori 





All data were obtained from the Clinical Data Analysis and Reporting System (CDARS) 
of the Hong Kong Hospital Authority. The CDARS records patient’s key information 
from all public hospitals and clinics, which has been described in previous studies.9-11 
The International Classification of Diseases, 9th revision (ICD-9), was used as the 
coding system. The accuracy of the coding for GIB has been verified previously.10 All 
data were anonymized. This study was approved by the Institutional Review Board of 
the University of Hong Kong and Hospital Authority Hong Kong West Cluster 
(Reference Number: UW 16-545). 
 
Study Design and Patients 
This was a retrospective territory-wide cohort study including all H. pylori-infected 
patients, aged 18 or above, who had received their first course of clarithromycin-
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containing triple therapy between Jan 2003 and Dec 2012.11-14 There is no restriction 
on indications for treatment and the usual practice is to eradicate all patients who are 
found to be H pylori positive due to a relatively high local incidence of gastric cancer 
and peptic ulcer. Clarithromycin-containing triple therapy was identified by the co-
prescription of clarithromycin with one proton pump inhibitors (PPI) and either 
amoxicillin or metronidazole with the same start date of prescriptions and overlapping 
duration of 7–14 days. Clarithromycin-containing triple therapy was the most 
commonly used empirical first-line therapy for H pylori eradication in Hong Kong with 
a high eradication rate during the study period.15 Patients who had prior H pylori 
therapy, cancer of any parts of the gastrointestinal tract, coagulant deficiency, surgical 
excision of any gastrointestinal tract segment, or esophageal varices at baseline were 
excluded (Figure 1). 
 
Follow up of H pylori treatment outcome was routinely conducted by either urea breath 
test or biopsy-based test. However, post-eradication H pylori status was not available 
in the database, and the success of treatment was inferred by the needs of subsequent 
retreatment in this study.12 Patients who presented with UGIB would have H pylori 
tested again and empirical retreatment without further confirmation was not practiced. 
Retreatment was identified by the repeated prescription of another course of 
clarithromycin-containing triple therapy, subsequent prescription of second-line 
(bismuth-based quadruple therapy and PPI-levofloxacin-amoxicillin) or third-line 
therapy (furazolidone, tetracycline or rifabutin-based therapy). 
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Patients were divided into two main groups according to need for retreatment for H. 
pylori. Those who received a single course of clarithromycin-containing triple therapy 
were considered as the reference group. Patients who required repeated therapy for H 
pylori were considered as the retreatment group. Retreatment group was further divided 
into three subgroups according to time between the first and last eradication therapies 
(≤3 months, 3–12 months, and >12 months). 
 
The observation period commenced from 30 days after the prescription of the last 
course of H pylori therapy until hospitalization for non-variceal UGIB, death or the end 
of the study (30 Jun 2016), whichever came first. The 30-day interval was chosen to 
allow for healing of any possible ulcers after eradication to avoid overestimation of 
bleeding risk.16 Secondary analysis was performed with start date from 30 days after 
the first eradication therapy and from 60 days after the last/first therapy (Figure 2). 
 
Outcome and Covariates 
The primary outcome was hospitalization for non-variceal UGIB, which was retrieved 
using the ICD-9 codes (Supplementary Table 1). For diagnosis with the code of 578.x, 
if the free text part of the record described the bleeding location, the specified one 
would be used. For other patients with an unspecified GIB, if there were new specified 




Baseline characteristics, concurrent medical conditions and medications were 
considered as covariates. Concurrent medication in the observational period were 
included as binary variables including gastroprotective agents (PPI and histamine type-
2 receptor antagonists [H2RA]), aspirin, other antiplatelet drugs, NSAIDs, 
anticoagulants (warfarin and new oral anticoagulants), corticosteroids, selective 
serotonin reuptake inhibitors (SSRI) and bisphosphonate. All medications were treated 
as time-varying variables, for which the follow-up period was split into 3-month 
intervals and drug use was defined as more than 7 days of use in each interval. Due to 
potential indication bias, the last 4 weeks before the index date of events or censoring 
were excluded for prescription records of PPI and H2RA. 
 
Data validation 
To validate the final H pylori statuses of patients, we retrieved the infection statuses of 
patients who hospitalized for UGIB in our hospital, the Queen Mary Hospital, which is 
a tertiary referral center and a university teaching hospital, by reviewing the detailed 
endoscopy reports, histology reports and/or urea breath test results. 
 
Statistical Analysis 
Continuous variables were expressed as median and interquartile range (IQR). 
Categorical variables were presented as numbers and percentages. Crude incidence 
rates of hospitalization for UGIB were calculated. Kaplan-Meier curves were fitted to 
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compare the proportion of patients without UGIB in different retreatment groups with 
the reference group. The multivariable time-dependent Cox proportional hazards 
regression model was used as the primary model to compare the risk of UGIB in the 
retreatment group with the reference group.17, 18 Adjusted hazard ratios (HR) with 
corresponding 95% confidence intervals (CI) were computed. 
 
In addition, propensity score (PS) matching analysis was performed as sensitivity 
analysis to control for the differences in baseline characteristics.19 PSs were estimated 
by logistic regression with the aforementioned covariates, in which drug use statuses in 
the first 3-month interval were used to calculate the scores. To reduce the effect of 
number of retreatments on the risk of UGIB, another sensitivity analysis was performed 
after excluding patients who received two or more retreatments. A sensitivity analysis 
using PUB as the endpoint was also performed. We further performed subgroup 
analyses by age (<60 or 60 years old), sex, history of UGIB/peptic ulcer, using 
gastroprotective agents or the presence of additional risk factors for UGIB (no risk 
factor vs more than one risk factor) using multivariable model. Additional risk factors 
include UGIB or ulcer history, use of aspirin, antiplatelet, NSAIDs, anticoagulants, 
corticosteroids or SSRI. Test for trend was assessed by modeling the treatment time 
interval as a continuous variable using the median value to each category. Tests with a 
two-sided P value less than 0.05 were regarded as statistical significance. All statistical 






A total of 70,518 patients (median age 54 years; male 46.3%) who had received the 
first course of triple therapy for H pylori were included, including 8330 (11.8%) 
patients who required retreatment (Figure 1). The median follow-up duration was 7.65 
(IQR 5.19–10.36) years. After stratification by the time between the first and last 
eradication therapy, there were 1173 (1.7%), 2162 (3.1%) and 4995 (7.1%) patients 
received the last retreatment with a delay of ≤3 months, 3–12 months and >12 months, 
respectively. Most of the patients (85.6%) who required retreatment received one 
course of retreatment only. The baseline characteristics are presented in Table 1. 
 
Data validation 
Validation of final H pylori infection statuses were performed in patients hospitalized 
for UGIB in the Queen Mary Hospital. Of the 130 patients who were subsequently 
hospitalized for UGIB, three (2.3%) were found to be positive for H pylori. 
 
Risk of hospitalization for UGIB in patients who received retreatment 
There were 1,882 patients who developed UGIB after the last H pylori eradication 
therapy. The specific causes of the UGIB events are present in Supplementary Table 
2 and no significant difference was observed between two groups (P = 0.075). The 
crude incidence rate of UGIB for all patients was 3.47 (95% CI 3.31–3.62) per 1000 
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person-years; and the incidence rate in the retreatment and reference group was 6.96 
(95% CI 6.28–7.68) and 3.08 (95% CI 2.93–3.24) per 1000 person-years, respectively. 
 
Compared to the reference group, patients who required retreatment have a higher risk 
of UGIB (multivariable adjusted HR 1.50, 95% CI 1.34–1.69; Table 2). It was 
consistent in PS matching analysis (HR 1.62, 95% CI 1.44–1.83), analysis after 
excluding patients who received ≥2 retreatments (HR 1.55, 95% CI 1.38–1.75) and 
analysis using PUB as endpoint (HR 1.46, 95% CI 1.21–1.78). 
 
The risk of UGIB in retreatment group was much higher in the secondary analysis with 
a different start date from 30 days after the first eradication therapy (multivariable 
adjusted HR 2.10, 95% CI 1.89–2.33; Table 2). In the analyses using 60 days after the 
first or last treatment as the start points, the findings were also consistent 
(Supplementary Table 3). 
 
Time between the first and last H pylori eradication therapies and the risk of UGIB 
The crude incidence rate of UGIB was 6.08 (95% CI 4.65–7.82), 5.05 (95% CI 4.04–
6.24) and 8.21 (95% CI 7.24–9.27) per 1000 person-years for patients with different 
time intervals of ≤3 months, 3–12 months and >12 months between first and last 
eradication therapies, respectively. Compared to the reference group, there was a 
progressive increase in rates of hospitalization for UGIB with the increasing time 
latency (P < 0.001; Figure 3A). The HRs also significantly increased with longer 
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interval between the first and last eradication except in patients who received 
retreatment within 3 months in the multivariable analysis (HR for ≤3 months: 1.16, 95% 
CI 0.88–1.54; 3–12 months: 1.35, 95% CI 1.07–1.69; >12 months: 1.68, 95% CI 1.46–
1.94, P for trend = 0.038). Similar results were obtained after excluding patients who 
received ≥2 retreatments (Table 2). The increased risk was also significant in the 
group >12 months, though the trend was not significant, in the PS matching analysis 
and analysis using PUB as the endpoint. 
 
When changing the start date of follow up to 30 days after the first eradication therapy, 
the trend was consistent (Figure 3B) and multivariable analysis also showed a time-
dependent increase in UGIB risk (HR for ≤3 months: 1.20, 95% CI 0.91–1.58; 3–12 
months: 1.80, 95% CI 1.47–2.22; >12 months: 2.47, 95% CI 2.19–2.79). When using 
60 days after the first or last treatment as the start points, the results were similar 
(Supplementary Table 3). 
 
In patients both with or without history of UGIB/peptic ulcer, higher risks of UGIB 
were observed in the retreatment group when compared to the reference group (with 
history of UGIB/peptic ulcer: HR 1.37, 95% CI 1.16–1.62; no history of UGIB/peptic 
ulcer: HR 1.69, 95% CI 1.44–1.98; Table 3). Similarly, higher UGIB risks were noted 
in the retreatment group irrespective the use statuses of gastroprotective agents but the 
HR was higher among non-users (users: HR 1.48, 95% CI 1.31–1.68; non-users: HR 
1.85, 95% CI 1.31–2.63). There were 15,447 (24.8%) patients who had more than one 
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additional risk factors for UGIB, and in both groups, retreatment were found to have 
higher risk of UGIB (more one additional risk factor: HR 1.29, 95% CI 1.28–1.66; no 
additional risk factor: HR 1.88, 95% CI 1.43–2.47). It was also consistent in subgroup 
analyses by age or sex. Subgroup analyses further showed that the increased UGIB risk 




In this territory-wide cohort study of more than 70,000 H pylori infected patients who 
had received clarithromycin-based eradication therapy, we evaluated the subsequent 
risk of hospitalization for UGIB in those who required retreatment after failure of initial 
eradication therapy. Specifically, we explored the association between different time 
from first to last treatment and UGIB risk. We found that patients who failed initial H 
pylori eradication had a 1.5-fold increase in risk of hospitalization for UGIB as 
compared to those who received a single course of therapy, which increased to 2.1-fold 
when followed up from the first treatment. Furthermore, a progressive increase in risk 
of UGIB with longer time intervals between the first and last treatment was observed. 
 
With the emerging problem of antimicrobial resistance, the success of conventional H 
pylori therapy is declining globally.6, 7 This is the first study to demonstrate that delay 
in retreatment for H pylori after failed initial eradication could lead to a significantly 
increase in risk of UGIB in a time-dependent manner. Although H pylori is a known 
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risk factor for PUB, there is so far no data to support the potential benefits of early 
retreatment in reducing the risk of hospitalization for UGIB among those who failed 
initial eradication. A previous retrospective cohort study compared early (≤120 days) 
versus late (>120 days) eradication therapy in patients hospitalized for peptic ulcer, and 
found that late H pylori eradication was associated with a higher risk of complicated 
recurrent peptic ulcers (HR 1.52, 95% CI 1.13–2.04).20 In keeping with this, a study 
from Sweden showed that the risk of complicated ulcer among patients with newly 
diagnosed peptic ulcer but delayed eradication therapy would increase with time (HR 
1.55 for 8–30 days to 6.14 for >365 days after diagnosis).5 Unlike the two previous 
studies that focused on primary eradication for H. pylori, the current study targeted on 
retreatment after initial treatment failure. 
 
The reasons for the higher risk of UGIB among those with delay in retreatment could 
be accounted by the observation that patients with H pylori eradication failure may have 
more severe gastric inflammation. Kalkan et al.8 found that the rates of severe gastritis 
as well as the presence of gastric atrophy and intestinal metaplasia were higher in the 
eradication failure group than those with successful eradication. On the other hand, 
higher H pylori density, which was associated with more severe histological changes, 
was also associated with lower eradication success of triple therapy.21, 22 Therefore, in 
addition to usual mechanism leading to eradication failure such as resistance to 
clarithromycin and poor compliance, patients in the retreatment group may have more 
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severe gastritis and higher density of H pylori at baseline, which may increase the 
subsequent risk of UGIB. 
 
In the subgroup analysis of users of gastroprotective agents, we found that retreatment 
was associated with an overall increased risk of hospitalization for UGIB in both users 
and non-users of gastroprotective agents. However, the risk was numerically lower 
among gastroprotective agent users than non-users (HR 1.48 vs 1.85). In the 
multivariable model of the primary analysis of all patients, we actually found that use 
of gastroprotective agents were associated with a lower risk of UGIB (HR 0.86, 95% 
CI 0.76–0.98). We speculate the reason for this observation may be related to the user 
definition as those who ever used gastroprotective agents in any 3-month intervals 
during follow-up period, rather than continuous or long-term use of gastroprotective 
agents, which may dilute the protective effects of gastroprotective agents on subgroup 
analysis. 
 
In this study, about 60% of patients who required retreatment had a time latency of 
more than 12 months between the first and last H pylori eradication therapies. Since 
our study was based on the electronic database, the exact reason for this delay could 
not be retrieved. However, we speculated that the main reason for the delays in 
retreatment was the extremely long waiting time in the public health care system for 
non-emergency services, such as elective endoscopy, urea breath test and outpatient 
appointment. Although the usual recommended testing interval for H pylori eradication 
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success is 6-8 weeks, most patients would need multiple appointments for examinations 
and clinic attendance which would culminate into considerable delay, particularly in 
patients with more than one course of failed eradication. 
 
The strength of this study was the inclusion of a large cohort of H pylori eradicated 
patients based on the public electronic healthcare database in Hong Kong. To adjust for 
potential confounders, we have performed different analyses including Cox model and 
PS matching analysis. In the multivariable model, medications were included as time-
varying covariates, which decreased the immortal time bias.23, 24 In addition, other 
sensitivity or subgroup analyses were performed to reduce potential biases. We have 
also performed sensitivity analysis on PUB which yielded consistent result. 
 
There were limitations of this study. First, successful H pylori eradication, which was 
not recorded in the database, was inferred by the use of a single course of eradication 
therapy. Some patients who failed eradication may not receive further therapy for 
various reasons not recovered in the electronic database. Nonetheless, the inclusion of 
patients who actually failed eradication in the reference group would only 
underestimate the risk of bleeding in the retreatment groups. Intuitively, those who 
failed multiple therapies are more likely to have persistent infection and hence higher 
risk of UGIB. Our sensitivity analysis also excluded difficult to treat patients who 
required 2 or more retreatments. Moreover, as the observation period starts from the 
last eradication therapy in the primary analysis, patients who presented with GIB would 
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have H pylori retested and retreatment given if positive, and the corresponding bleeding 
episode would not be included in the current observation period if it occurred before 
the last therapy. In the validation analysis, only 2.3% patients who were retested for H 
pylori were found positive and none of them were in the retreatment group, arguing 
against that persistent H pylori infection was the reason for the higher risk of bleeding 
in the retreatment group. Second, we included patients with all indications for H pylori 
eradication rather than focusing on patients with high risk of UGIB. However, with the 
wide inclusion, our results would be more generalizable to all H pylori infected patients, 
irrespective of their baseline endoscopic diagnoses and medical conditions. Third, we 
used all UGIB as primary outcome rather than limiting to PUB alone as we believed 
these findings would be more generalizable.  
 
CONCLUSION 
In this territory-wide study of H. pylori-infected patients who had received eradication 
therapy, we found that patients who failed by initial therapy had a 1.5-fold increase in 
UGIB risk, which progressively increased with longer delay between initial and final 
eradication therapies. Early retreatment, preferably within 3 months, should be 
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Figure 1 Selection of study patients. 
 
Figure 2 Schematic diagram of the study design. 
Retreatment group may receive one or more retreatment. 
 
Figure 3 Age and sex adjusted Kaplan-Meier curves of UGIB in patients with different 
time between the first and last H pylori eradication therapy comparing to patients 
without retreatment.  
A: primary analysis with 30 days after the last eradication therapy as the start point; B: 
secondary analysis with 30 days after the first eradication therapy as the start point. 
  
 24






Time interval between the first and last eradication 
therapy in the retreatment group 
≤3 months 3–12 months >12 months 
No. of patients (%) 62,188 (88.2) 8330 (11.8) 1173 (1.7) 2162 (3.1) 4995 (7.1) 
Age, year (IQR) 53.0 (45.0–64.0) 56.0 (47.0, 68.0) 56.0 (45.0, 70.0) 54.0 (45.0, 65.0) 58.0 (48.0, 69.0) 
Male (%) 28,791 (46.3) 3865 (46.4) 578 (49.3) 957 (44.3) 2330 (46.6) 




6.31 (3.53, 9.22) 
7.42 (4.89, 
10.08) 
6.98 (4.48, 9.67) 5.58 (2.80, 8.79) 
Baseline conditions, no. 
(%) 
     
UGIB or ulcer history 8858 (14.2) 1676 (20.1) 327 (27.9) 432 (20.0) 917 (18.4) 
Ischemic heart disease 2661 (4.3) 539 (6.5) 72 (6.1) 109 (5.0) 358 (7.2) 
Stroke 1771 (2.8) 370 (4.4) 66 (5.6) 74 (3.4) 230 (4.6) 
Hypertension 5087 (8.2) 1019 (12.2) 166 (14.2) 206 (9.5) 647 (13.0) 
Diabetes 3443 (5.5) 644 (7.7) 94 (8.0) 143 (6.6) 407 (8.1) 
Renal disease 798 (1.3) 194 (2.3) 28 (2.4) 47 (2.2) 119 (2.4) 
Intracranial 
hemorrhage 
273 (0.4) 53 (0.6) 5 (0.4) 14 (0.6) 34 (0.7) 
Cirrhosis 215 (0.3) 42 (0.5) 4 (0.3) 11 (0.5) 27 (0.5) 
Medications, no. (%) *      
Gastroprotective 
agents 
37,384 (60.1) 5714 (68.6) 790 (67.3) 1435 (66.4) 3489 (69.8) 
PPI 10,843 (17.5) 2345 (28.2) 369 (31.5) 545 (25.2) 1431 (28.6) 
H2RA 30,795 (49.6) 4247 (51.0) 569 (48.5) 1103 (51.0) 2575 (51.6) 
Aspirin 5252 (8.4) 938 (11.3) 123 (10.5) 193 (8.9) 622 (12.5) 
Antiplatelet 708 (1.1) 140 (1.7) 27 (2.3) 22 (1.0) 91 (1.8) 
NSAIDs 2833 (4.6) 558 (6.7) 68 (5.8) 125 (5.8) 365 (7.3) 
Anticoagulants 334 (0.5) 67 (0.8) 14 (1.2) 11 (0.5) 42 (0.8) 
Corticosteroids 610 (1.0) 179 (2.1) 35 (3.0) 50 (2.3) 94 (1.9) 
SSRI 1117 (1.8) 278 (3.3) 32 (2.7) 56 (2.6) 190 (3.8) 
Bisphosphonate 129 (0.2) 26 (0.3) 4 (0.3) 3 (0.1) 19 (0.4) 
 25
CI, confidence interval; H2RA, histamine type-2 receptor antagonists; IQR, interquartile range; 
UGIB, upper gastrointestinal bleeding; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, 
proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors. 
* Drug using status in the first 3-month interval. 
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(95% CI) * 
PS matching 
HR (95% CI) 
Excluding 
patients with 2 
retreatments† 
Using PUB as the 
endpoint† 
Start date: 30 days after the last eradication therapy (Primary analysis) 
Reference group 1.00 
Retreatment group 2.21 (1.98–2.48) 1.50 (1.34–1.69) 1.62 (1.44–1.83) 1.55 (1.38–1.75) 1.46 (1.21–1.78) 
≤3 months 1.96 (1.49–2.58) 1.16 (0.88–1.54) 1.38 (1.03–1.85) 1.18 (0.88–1.56) 0.80 (0.47–1.35) 
3–12 months 1.62 (1.29–2.04) 1.35 (1.07–1.69) 1.22 (0.96–1.54) 1.46 (1.16–1.85) 1.30 (0.89–1.89) 
>12 months 2.59 (2.26–2.97) 1.68 (1.46–1.94) 1.90 (1.65–2.19) 1.72 (1.48–1.99) 1.77 (1.41–2.22) 
P for trend < 0.001 0.038 0.178 0.006 0.515 
Start date: 30 days after the first eradication therapy (Secondary analysis) 
Reference group 1.00 
Retreatment group 2.59 (2.34–2.86) 2.10 (1.89–2.33) 2.18 (1.97–2.42) 2.07 (1.86–2.31) 2.53 (2.15–2.98) 
≤3 months 1.97 (1.50–2.59) 1.20 (0.91–1.58) 1.65 (1.25–2.17) 1.25 (0.94–1.67) 0.83 (0.50–1.40) 
3–12 months 2.00 (1.63–2.46) 1.80 (1.47–2.22) 1.70 (1.39–2.09) 1.81 (1.46–2.24) 2.19 (1.61–2.99) 
>12 months 2.95 (2.63–3.30) 2.47 (2.19–2.79) 2.49 (2.21–2.80) 2.39 (2.11–2.71) 3.24 (2.70–3.88) 
P for trend < 0.001 < 0.001 < 0.001 < 0.001 0.001 
CI, confidence interval; HR, hazard ratio; PUB, peptic ulcer bleeding. 
* Adjusted for age, sex, comorbidities and concurrent medications; 
† Multivariable model. 
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Table 3 Subgroup analyses of the risk of UGIB and retreatment 
Subgroups 
Multivariable adjusted 
HR (95% CI) * 
Subgroups 
Multivariable adjusted 
HR (95% CI) * 
Age <60 years old  Age 60 years old  
Retreatment group 1.67 (1.30–2.14) Retreatment group 1.53 (1.34–1.75) 
≤3 months 0.87 (0.43–1.79) ≤3 months 1.30 (0.96–1.76) 
3–12 months 1.11 (0.67–1.83) 3–12 months 1.44 (1.11–1.86) 
>12 months 2.32 (1.73–3.11) >12 months 1.64 (1.40–1.93) 
Female  Male  
Retreatment group 1.52 (1.27–1.82) Retreatment group 1.52 (1.30–1.77) 
≤3 months 1.35 (0.90–2.03) ≤3 months 1.05 (0.72–1.54) 
3–12 months 1.31 (0.92–1.86) 3–12 months 1.38 (1.02–1.87) 
>12 months 1.65 (1.33–2.06) >12 months 1.72 (1.43–2.08) 
With UGIB or ulcer 
history 
 
Without UGIB or ulcer 
history 
 
Retreatment group 1.37 (1.16–1.62) Retreatment group 1.69 (1.44–1.98) 
≤3 months 1.17 (0.83–1.65) ≤3 months 1.17 (0.73–1.88) 
3–12 months 1.18 (0.86–1.63) 3–12 months 1.57 (1.14–2.17) 









Retreatment group 1.48 (1.31–1.68) Retreatment group 1.85 (1.31–2.63) 
≤3 months 1.07 (0.79–1.46) ≤3 months 1.53 (0.43–3.13) 
3–12 months 1.39 (1.10–1.77) 3–12 months 0.97 (0.44–2.13) 
>12 months 1.64 (1.41–1.90) >12 months 2.62 (1.74–3.92) 
More than one (≥2) 
additional risk factor‡ 
 
No additional risk 
factors‡ 
 
Retreatment group 1.29 (1.08–1.55) Retreatment group 1.88 (1.43–2.47) 
≤3 months 1.12 (0.74–1.70) ≤3 months 1.27 (0.58–2.81) 
3–12 months 1.27 (0.90–1.81) 3–12 months 0.96 (0.50–1.84) 
>12 months 1.35 (1.08–1.68) >12 months 2.47 (1.80–3.39) 
CI, confidence interval; HR, hazard ratio; UGIB, upper gastrointestinal bleeding. 
 28
* The reference group is patients without retreatment in each subgroup. 
† Users of gastroprotective agents were those who ever used gastroprotective agents in any 3-month 
intervals during follow-up period. 
‡ Additional risk factors, in any 3-month intervals during follow-up period, include UGIB or ulcer 
history, use of aspirin, antiplatelet, NSAIDs, anticoagulants, corticosteroids or SSRI. Other 
covariates in subgroup of no additional risk factors and all covariates in subgroup with more than 
one additional risk factors were also adjusted. 
